First human test of new cancer drug halted early
NCT ID NCT04249843
Summary
This early-stage study aimed to test the safety and find the right dose of an experimental drug called BGB-3245 in people with advanced solid tumors that had stopped responding to other treatments. It specifically enrolled patients whose tumors had certain genetic changes in the BRAF gene. The study was terminated, and its main goal was to understand how the body processes the drug and what side effects it might cause.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blacktown Hospital
Blacktown, New South Wales, 2148, Australia
-
Cedars Sinai Medical Center
Beverly Hills, California, 90212, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
One Clinical Research
Nedlands, Perth, 6009, Australia
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 2010, Australia
-
The Kinghorn Cancer Centre, St Vincent Hospital Sydney
Sydney, New South Wales, 2010, Australia
-
University of Virginia Comprehensive Cancer Centre
Charlottesville, Virginia, 22903, United States
Conditions
Explore the condition pages connected to this study.